Better Home & Finance reported a 75% sequential and 39% year-over-year increase in net loss for Q1 2026, while drastically lowering its expected monthly loan volume from $1 billion to $550 million. This significant shortfall led to a 28% drop in its share price on May 7, 2026, and prompted a securities class action alleging the company misled investors about its growth prospects. The CEO was fired after the class period, and a shareholder rights firm is investigating potential violations of securities laws. Investors who suffered losses are encouraged to submit claims before the November 20, 2026 deadline.
Better Home & Finance's Q1 2026 net loss surged 75% sequentially, alongside a sharp cut in loan volume forecasts. For readers following the Financials sector, here is Pluang's market snapshot as of Sep 24, 2026 23:04 WIB: out of 85 priced US Financials stocks, 16 rose and 67 fell. Notable movers include APO at USD 118.97 with 100% sell order activity, MARA at USD 12.92 with 79% buy order activity, and KKR at USD 94.49 with 100% sell order activity.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
